<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270656</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0449</org_study_id>
    <nct_id>NCT04270656</nct_id>
  </id_info>
  <brief_title>Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 With Non-alcoholic Hepatic Steatosis</brief_title>
  <acronym>STEATO-POMPE</acronym>
  <official_title>Liver and Metabolic Effects of Insulin Pump Therapy in a Population of Type 2 Diabetics With Non-alcoholic Hepatic Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of fatty liver disease (NAFLD: Non-Alcoholic Fatty Liver Disease or to a more&#xD;
      severe degree NASH: Non-Alcoholic SteatoHepatitis) reached 40-70% in subjects with type 2&#xD;
      diabetes (T2D). NAFLD can be easily detected by performing a hepatic ultrasonography. The&#xD;
      presence of a NAFLD is positively correlated with the severity of insulin resistance and&#xD;
      dysglycemia in this population. The presence of NAFLD worsens the prognosis of T2D with an&#xD;
      increased cardiovascular risk. This hepatic impairment would also increase the risk of&#xD;
      microvascular complications, especially nephropathy. Conversely, T2D increases the risk of&#xD;
      transition from NAFLD to NASH and then to hepatic fibrosis and its related complications&#xD;
      (cirrhosis, hepatocellular carcinoma). The risk of progression of liver steatosis to fibrosis&#xD;
      is also more important as diabetes and insulin resistance are more severe.&#xD;
&#xD;
      In addition to diabetes and insulin resistance, other risk factors are associated with more&#xD;
      severe liver damage such as changes in microbiota. Indeed, it has already been described a&#xD;
      smaller amount of bacteroides in the microbiota of subjects with T2D and the most severe&#xD;
      hepatic impairment. The treatment of NAFLD/NASH is poorly codified without approved drugs in&#xD;
      this indication, while many phase 3 trials with candidate drugs are undergoing. Life-style&#xD;
      measures (physical activity and low carbohydrate/calorie diet) can limit the progression from&#xD;
      NAFLD to more severe liver fibrosis. Some bariatric surgery studies have also shown good&#xD;
      results in this situation. Pharmacological interventions are also reported with proven&#xD;
      efficacy of pioglitazone, vitamin E and orlistat.&#xD;
&#xD;
      The OPT2MISE study has recently shown the superiority of insulin pump (or continuous&#xD;
      sub-cutaneous insulin infusion: CSII) compared to multiple daily insulin injections (MDI) to&#xD;
      improve glycemic control in a population of patients with T2D in failure of well-titrated&#xD;
      MDI. In addition, treatment with CSII showed a 45% decrease in insulin resistance (assessed&#xD;
      by HOMA-IR) in a population of newly diagnosed T2D.&#xD;
&#xD;
      In light of these data, investigators hypothesize that the introduction of insulin pump&#xD;
      treatment in a population of subjects with T2D and NAFLD, by improving insulin sensitivity,&#xD;
      could reduce fatty liver content compared to standard MDI treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">April 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of hepatic steatosis, between the insulin pump therapy (CSII) vs Multi injection treatement (MDI) groups.</measure>
    <time_frame>6 months</time_frame>
    <description>Change of fatty liver by MRI quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In the CSII group : avantage of an insulin pump treatment on the fatty liver between inclusion and the 6th month,</measure>
    <time_frame>6 months</time_frame>
    <description>Variation of hepatic steatosis (MRI quantization by gradient echo sequences &amp; centralized reading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the CSII group : avantage of an insulin pump treatment on the fatty liver (quantified by MRI), between inclusion and the 12th month,</measure>
    <time_frame>12 months</time_frame>
    <description>Variation of hepatic steatosis (MRI quantization by gradient echo sequences &amp; centralized reading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months, on hepatic biological parameters and non-invasive biomarkers of fatty liver (FLI) and of fibrosis of the liver (FIB-4 and NAFLD Score),</measure>
    <time_frame>6 months</time_frame>
    <description>Liver fonction (AST ; ALAT ; GGT ; PAL ; Ferritin) Test-fibrosis score criteria (FIB- 4 and NAFLD Score) ; FLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>dosage of plasma adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>calculation of the modified HOMA-IR index (peptide C, blood sugar),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on glycemic balance</measure>
    <time_frame>6 months</time_frame>
    <description>HbA1c dosages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on the total daily insulin dose</measure>
    <time_frame>6 months</time_frame>
    <description>daily insulin dose record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>triglycerides (TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>fatty-free acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on lipid profile • the inflammatory condition</measure>
    <time_frame>6 months</time_frame>
    <description>ApoB,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of a CSII vs MDI treatment, between randomization and 6 months on CRPus</measure>
    <time_frame>6 months</time_frame>
    <description>Ultra-sensitive C-reactive protein (CRPus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>DTSQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>SF36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis at 6 months: comparison the first 6 months, in the CSII and MDI groups:</measure>
    <time_frame>6 months</time_frame>
    <description>Reporting by patient of all severe hypoglycemia during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis at 6 months: comparison the first 6 months, in the CSII and MDI groups:</measure>
    <time_frame>6 months</time_frame>
    <description>Reporting by the patient of all episode of ketoacidosis during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the sensitivity values of the FLI for the detection of fatty liver in this population,</measure>
    <time_frame>6 months</time_frame>
    <description>quantification of hepatic MRI as Gold Standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the specificity values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.</measure>
    <time_frame>6 months</time_frame>
    <description>quantification of hepatic MRI as Gold Standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the positive predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.</measure>
    <time_frame>6 months</time_frame>
    <description>quantification of hepatic MRI as Gold Standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation negative predictive values of the FLI for the detection of fatty liver in this population, by using the quantification of hepatic MRI as Gold Standard.</measure>
    <time_frame>6 months</time_frame>
    <description>quantification of hepatic MRI as Gold Standard.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Type 2 Diabetes (T2D)</condition>
  <arm_group>
    <arm_group_label>Insulin pump therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-injection treatment ( MDI ).</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Insulin pump therapy</intervention_name>
    <description>5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)</description>
    <arm_group_label>Insulin pump therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multi-injection treatment ( MDI ).</intervention_name>
    <description>Corresponds to an outpatient visit if the patient is randomized into the multi-injection group</description>
    <arm_group_label>Multi-injection treatment ( MDI ).</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male / female 35/70 years (including ranges) with T2D ≥ 1 year&#xD;
&#xD;
          -  Benefiting from the indication of use of the free Freestyle glucose meter&#xD;
&#xD;
          -  Treatment with multi-injection insulin therapy comprising a daily injection of basal&#xD;
             insulin (Glargine U100, Glargine U300, Degludec) and at least 2 daily injections of an&#xD;
             insulin analogue (lispro, aspart or glulisine) +/- metformin, dipeptidyl peptidase-4&#xD;
             (DPP4) and/or sodium-glucose cotransporter type 2 (SGLT2) at a dose stable for at&#xD;
             least 3 months.&#xD;
&#xD;
          -  For women of childbearing age, oestro-progestative pill, IUD, implant.&#xD;
&#xD;
          -  11% ≥ HbA1c ≥ 6.5%&#xD;
&#xD;
          -  Presence of hepatic steatosis according to the ultrasonography&#xD;
&#xD;
          -  Absence of chronic alcoholic intoxication&#xD;
&#xD;
          -  Absence of chronic viral hepatitis or other chronic liver diseases (eg hemochromatosis&#xD;
             ...)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Contraindication to pump treatment&#xD;
&#xD;
          -  Treatment with anti-diabetics or other than metformin, dipeptidyl peptidase-4 (DPP4)&#xD;
             and/or sodium-glucose cotransporter type 2 (SGLT2)&#xD;
&#xD;
          -  Treatment with basal inulin of Levemir&#xD;
&#xD;
          -  Contraindication to performing MRI&#xD;
&#xD;
          -  Chronic alcohol abuse (after alcohol consumption&gt; 20g / day in men and&gt; 10g / day in&#xD;
             women) according to the medical examination&#xD;
&#xD;
          -  Chronic viral hepatitis based on HBV and HCV serology results&#xD;
&#xD;
          -  Hemochromatosis according to the martial assessment&#xD;
&#xD;
          -  Other toxic or drug hepatitis&#xD;
&#xD;
          -  Severe hepatic pathology: hepatic cirrhosis, hepatocellular carcinoma&#xD;
&#xD;
          -  Severe renal insufficiency (MDRD &lt;30 ml / min)&#xD;
&#xD;
          -  Severe and progressive cardiovascular pathology&#xD;
&#xD;
          -  Treatment (permanent or intermittent) with glucocorticoids&#xD;
&#xD;
          -  Treatment known to improve hepatic steatosis (glitazone, vitamin E, orlistat)&#xD;
&#xD;
          -  history or bariatric surgery project for the duration of the study&#xD;
&#xD;
          -  Drug treatment likely to cause hepatic steatosis (amiodarone, carbamazepine,&#xD;
             tamoxifen, valproate, clozapine, anti-retroviral drugs) unless the dose has been&#xD;
             stable for ≥ 3 months&#xD;
&#xD;
          -  Guardianship, curatorship or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>37 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthieu Pichelin</last_name>
    <phone>02.53.48.27.06</phone>
    <email>matthieu.pichelin@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BRIET</last_name>
    </contact>
    <investigator>
      <last_name>Claire BRIET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michaël JOUBERT, MD</last_name>
      <email>joubert-m@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Michaël JOUBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel Petit, MD</last_name>
      <phone>05.46.45.51.31</phone>
    </contact>
    <investigator>
      <last_name>Jean-Michel PETIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>La Rochette</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier GOUET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier GOUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrielle CAUSSY, MD</last_name>
      <phone>04 78 86 14 89</phone>
    </contact>
    <investigator>
      <last_name>Cyrielle CAUSSY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes UH</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Pichelin</last_name>
      <email>matthieu.pichelin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand Cariou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier PIGUEL, MD</last_name>
      <phone>05.49.44.40.34</phone>
    </contact>
    <investigator>
      <last_name>Xavier PIGUEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle GUILHEM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle GUILHEM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Gourdy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre GOURDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

